APO-TRAVOPROST-TIMOP PQ 0.5 %
TIMOLOL (TIMOLOL MALEATE) : 0.5 % TRAVOPROST : 0.004 % · DIN 02415305 · APOTEX INC
Health Canada status: MARKETED
What is APO-TRAVOPROST-TIMOP PQ?
APO-TRAVOPROST-TIMOP PQ 0.5 % contains TIMOLOL (TIMOLOL MALEATE) : 0.5 % TRAVOPROST : 0.004 %. It is listed in the Health Canada Drug Product Database under DIN 02415305, held by APOTEX INC, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 03-Mar-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-TRAVOPROST-TIMOP PQ used for?
Reduction of elevated IOP in adults with open-angle glaucoma or ocular hypertension insufficiently responsive to beta-blockers, prostaglandins, or other IOP lowering agents. Not for initiation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02415305 |
|---|---|
| Brand name | APO-TRAVOPROST-TIMOP PQ |
| Generic / active ingredient | TIMOLOL (TIMOLOL MALEATE) : 0.5 % TRAVOPROST : 0.004 % |
| Manufacturer | APOTEX INC |
| Strength | 0.5 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01ED51 TIMOLOL, COMBINATIONS |
| AHFS class | 52:40.28 ; 52:40.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 03-Mar-2020 |
| Original market date | 2018-12-06 00:00:00 |
How is it administered?
One drop in the affected eye(s) once-daily (morning or evening). Do not exceed once-daily. Nasolacrimal occlusion or closing eyelid for 2 minutes after application is recommended.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in the provided text snippet (refer to section 11 of full monograph).
How is it supplied?
White, opaque, polypropylene bottle with translucent dropper and white cap. Supplied as 2.5 mL or 5 mL fill size.
Contraindications
Hypersensitivity; reactive airway diseases (asthma); severe COPD; sinus bradycardia; sick sinus syndrome; AV block (2nd/3rd degree); overt cardiac failure; cardiogenic shock; pregnancy.
Warnings and precautions
Systemic absorption may occur; risk of severe respiratory/cardiac reactions; may change eye color (permanent), eyelid skin, and eyelashes; use caution in patients with active inflammation or diabetes.
What can be used instead?
Other Canadian products sharing ATC code S01ED51 TIMOLOL, COMBINATIONS. 21 of 50 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BRIMONIDINE-TIMOP | 0.5 % | SOLUTION | APOTEX INC | MARKETED | DIN 02375311 |
| APO-DORZO-TIMOP | 5 MG | SOLUTION | APOTEX INC | MARKETED | DIN 02299615 |
| AZARGA | 0.5 % | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02331624 |
| COMBIGAN | 0.2 % | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02248347 |
| COSOPT | 5 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | DIN 02240113 |
| COSOPT PRESERVATIVE-FREE | 20 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | DIN 02258692 |
| DORZOLAMIDE-TIMOLOL | 20 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02522020 |
| DUOTRAV PQ | 0.5 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02278251 |
| JAMP BRIMONIDINE/TIMOLOL | 0.2 % | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02531704 |
| JAMP-LATANOPROST/TIMOLOL | 5 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02453770 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.